CHMP Positive On Descovy, A Safer HIV Therapy?
This article was originally published in The Pink Sheet Daily
Tenofovir alafenamide-based regimens could drive the growth of the anti-HIV market for next several years.
You may also be interested in...
Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.
Amgen, Celgene, Mylan and Gilead were among the companies that provided business updates at the Cowen and Co. Healthcare conference and Raymond James Institutional Investors conference.
The latest drug development news and highlights from our FDA Performance Tracker.